Literature DB >> 12573241

Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases.

Beston F Nore1, Pekka T Mattsson, Per Antonsson, Carl-Magnus Bäckesjö, Anna Westlund, Johan Lennartsson, Henrik Hansson, Peter Löw, Lars Rönnstrand, C I Edvard Smith.   

Abstract

Tec family protein tyrosine kinases (TFKs) play a central role in hematopoietic cellular signaling. Initial activation takes place through specific tyrosine phosphorylation situated in the activation loop. Further activation occurs within the SH3 domain via a transphosphorylation mechanism, which for Bruton's tyrosine kinase (Btk) affects tyrosine 223. We found that TFKs phosphorylate preferentially their own SH3 domains, but differentially phosphorylate other member family SH3 domains, whereas non-related SH3 domains are not phosphorylated. We demonstrate that SH3 domains are good and reliable substrates. We observe that transphosphorylation is selective not only for SH3 domains, but also for dual SH3SH2 domains. However, the dual domain is phosphorylated more effectively. The major phosphorylation sites were identified as conserved tyrosines, for Itk Y180 and for Bmx Y215, both sites being homologous to the Y223 site in Btk. There is, however, one exception because the Tec-SH3 domain is phosphorylated at a non-homologous site, nevertheless a conserved tyrosine, Y206. Consistent with these findings, the 3D structures for SH3 domains point out that these phosphorylated tyrosines are located on the ligand-binding surface. Because a number of Tec family kinases are coexpressed in cells, it is possible that they could regulate the activity of each other through transphosphorylation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573241     DOI: 10.1016/s1570-9639(02)00524-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase.

Authors:  Mohamed A Eldeeb; Richard P Fahlman
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

2.  Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.

Authors:  Yiming Zhong; Amy J Johnson; John C Byrd; Jason A Dubovsky
Journal:  Postdoc J       Date:  2014-06

3.  Conformational snapshots of Tec kinases during signaling.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

4.  T cell specific adapter protein (TSAd) interacts with Tec kinase ITK to promote CXCL12 induced migration of human and murine T cells.

Authors:  Tone Berge; Vibeke Sundvold-Gjerstad; Stine Granum; Thorny C B Andersen; Gunn B Holthe; Lena Claesson-Welsh; Amy H Andreotti; Marit Inngjerdingen; Anne Spurkland
Journal:  PLoS One       Date:  2010-03-18       Impact factor: 3.240

5.  Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.

Authors:  Sen Chen; Xinnong Jiang; Christina A Gewinner; John M Asara; Nicholas I Simon; Changmeng Cai; Lewis C Cantley; Steven P Balk
Journal:  Sci Signal       Date:  2013-05-28       Impact factor: 8.192

Review 6.  ITK inhibitors in inflammation and immune-mediated disorders.

Authors:  Nisebita Sahu; Avery August
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

7.  SH2-dependent autophosphorylation within the Tec family kinase Itk.

Authors:  Raji E Joseph; Andrew Severin; Lie Min; D Bruce Fulton; Amy H Andreotti
Journal:  J Mol Biol       Date:  2009-06-11       Impact factor: 5.469

8.  Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.

Authors:  Alexander P Bye; Amanda J Unsworth; Michael J Desborough; Catherine A T Hildyard; Niamh Appleby; David Bruce; Neline Kriek; Sophie H Nock; Tanya Sage; Craig E Hughes; Jonathan M Gibbins
Journal:  Blood Adv       Date:  2017-12-12

9.  Itk: the rheostat of the T cell response.

Authors:  Juris A Grasis; Constantine D Tsoukas
Journal:  J Signal Transduct       Date:  2011-04-07

Review 10.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.